Combining Genomics and Imageomics to Predict the Sensitivity of Neoadjuvant Pemetrexed and Cisplatin Chemotherapy in Patients With Lung Adenocarcinoma

January 5, 2022 updated by: Shanghai Zhongshan Hospital
Combining genomics and imageomics to predict the sensitivity of neoadjuvant pemetrexed and cisplatin chemotherapy in patients with lung adenocarcinoma

Study Overview

Status

Not yet recruiting

Conditions

Intervention / Treatment

Study Type

Observational

Enrollment (Anticipated)

50

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years to 75 years (ADULT, OLDER_ADULT)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Sampling Method

Non-Probability Sample

Study Population

Neoadjuvant pemetrexed and cisplatin chemotherapy in patients with lung adenocarcinoma

Description

Inclusion Criteria:

  • 1. Aged between 18 and 75 years;
  • 2. Lung adenocarcinoma;
  • 3. The patient is able to receive neoadjuvant pemetrexed and cisplatin chemotherapy
  • 4 .The patient is able to understand and comply with the study and has provided written informed consent.

Exclusion Criteria:

  • 1. Patients with a history of lung surgery;
  • 2. Postoperative pathology showed non-primary lung cancer;
  • 3. Patients with a history of other tumors;
  • 4. Patients with severe complications (coronary heart disease, valvular heart disease, end-stage renal disease, severe liver cirrhosis);
  • 5. Unable to cooperate with the researchers because of dementia or cognitive decline
  • 6. Other situations that are not in conformity with the standards and requirements of this trial.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

Cohorts and Interventions

Group / Cohort
Intervention / Treatment
neoadjuvant pemetrexed and cisplatin chemotherapy in patients with lung adenocarcinoma
Other: Neoadjuvant pemetrexed and cisplatin chemotherapy
neoadjuvant pemetrexed and cisplatin chemotherapy in patients with lung adenocarcinoma

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Time Frame
Tumor Regression Grade
Time Frame: 1-2 Weeks after enrollment (after Surgery)
1-2 Weeks after enrollment (after Surgery)

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Shanghai Zhongshan Hospital

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (ANTICIPATED)

January 1, 2022

Primary Completion (ANTICIPATED)

December 31, 2024

Study Completion (ANTICIPATED)

December 31, 2024

Study Registration Dates

First Submitted

December 18, 2021

First Submitted That Met QC Criteria

January 5, 2022

First Posted (ACTUAL)

January 11, 2022

Study Record Updates

Last Update Posted (ACTUAL)

January 11, 2022

Last Update Submitted That Met QC Criteria

January 5, 2022

Last Verified

December 1, 2021

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

  • B2021-Zhan

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Subscribe